EUVIMEDEUVIMED entdecken
Open Access

Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy

Weikang Xu, Minli Hu, Xinyu Lu, Yueqiong Lao, Na Ma, Yiyue Wang, Jing Li, Xingyuan Chen, Shiming Liu, Jing Liu, Wei Zhu, Hui Yang

International Journal of Biological Sciences · 2024 · 20 (10) · 3942-3955

DOI: 10.7150/ijbs.93668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Weikang Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Proprotein Convertase 9, Immunotherapy. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProprotein Convertase 9ImmunotherapyCD8-Positive T-LymphocytesHumansAnimalsMiceProgrammed Cell Death 1 ReceptorCell Line, TumorTumor MicroenvironmentPCSK9 InhibitorsMice, Inbred C57BLReceptors, Antigen, T-CellMale

Stichwörter der Autor:innen

TCR-engineered T cell (TCR-T)hepatocellular carcinoma (HCC)low-density lipoprotein receptor (LDLR)proprotein convertase subtilisin/kexin 9 (PCSK9)

Substanzen

Proprotein Convertase 9PCSK9 protein, humanProgrammed Cell Death 1 ReceptorPCSK9 InhibitorsReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research; Key Laboratory of Infectious Diseases Research in South China, Ministry…
  • Department of Pathology, The First People's Hospital of Foshan, Foshan 528000, China.
  • Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
  • Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.

Zitieren

APA

Xu, W., Hu, M., Lu, X., Lao, Y., Ma, N., Wang, Y., Li, J., Chen, X., Liu, S., Liu, J., Zhu, W., & Yang, H. (2024). Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy. International Journal of Biological Sciences, 20(10), 3942-3955. https://doi.org/10.7150/ijbs.93668

Vancouver

Xu W, Hu M, Lu X, Lao Y, Ma N, Wang Y, et al. Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy. International Journal of Biological Sciences. 2024;20(10):3942-3955. doi:10.7150/ijbs.93668

BibTeX
@article{Xu2024,
  author = {Xu, Weikang and Hu, Minli and Lu, Xinyu and Lao, Yueqiong and Ma, Na and Wang, Yiyue and Li, Jing and Chen, Xingyuan and Liu, Shiming and Liu, Jing and Zhu, Wei and Yang, Hui},
  title = {Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy},
  journal = {International Journal of Biological Sciences},
  year = {2024},
  volume = {20},
  number = {10},
  pages = {3942--3955},
  doi = {10.7150/ijbs.93668}
}
Kostenlos starten →